Quantcast
Last updated on April 19, 2014 at 9:20 EDT
Studies Investigate New Less Toxic Treatments For Hepatitis

Studies Investigate New, Less Toxic Treatments For Hepatitis C

redOrbit Staff & Wire Reports - Your Universe Online A new orally-administered antiviral therapy has reportedly cured hepatitis C infection in over 90 percent of patients with liver cirrhosis, according to research published Saturday in the...

Latest Hepatitis Stories

2014-04-17 15:40:57

Deaths from viral Hepatitis B and C have surpassed HIV/AIDS in many countries, including Australia and in Western Europe, according to an analysis of the 2010 Global Burden of Disease study. The analysis was conducted by Dr Benjamin Cowie and Ms Jennifer MacLachlan from the University of Melbourne and Melbourne Health, and was presented at The International Liver Congress in London earlier this month. “Liver cancer is the fastest increasing cause of cancer deaths in Australia,...

2014-04-14 12:51:21

The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase...

2014-04-14 12:35:09

Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients. Overall, 65.4% of patients...

2014-04-14 12:33:05

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Adel Jebar of the Leeds Institute of Cancer and Pathology, University of Leeds, presented a poster at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Combined anti-viral and anti-tumour therapy for virus-associated liver cancer," covered preclinical research into the treatment of hepatocellular...

2014-04-14 12:30:21

A UK study investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity. The research, conducted by the King's College Hospital Paediatric Liver Centre and the University of Surrey's School of Biosciences and Medicine, and funded by the Children's Liver Disease Foundation retrospectively analyzed the medical records of 120 pediatric patients with NAFLD. The...

2014-04-14 12:28:15

Exciting new data presented today at the International Liver Congress™ 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD). Though an early stage animal model, the French study highlights the possibility of preventing ALD with faecal microbiota transplantation – the engrafting of new microbiota, usually through administering human faecal material from a healthy donor into the colon of a recipient. In the study, two groups of...

2014-04-12 12:20:06

LONDON, April 12, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93 percent of patients with the hepatitis C virus (HCV) and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated with simeprevir administered once daily with Gilead Sciences, Inc.'s sofosbuvir for 12 weeks achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The addition of...

2014-04-12 00:21:23

- In patients with compensated liver cirrhosis and genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, a difficult-to-treat population, TURQUOISE-II demonstrated SVR(12) rates of 91.8 and 95.9 percent after 12 and 24 weeks of treatment, respectively LONDON, April 12, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver Congress(TM) (ILC) 2014. Data from a pivotal phase...

2014-04-11 12:58:41

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014. GBD 2010 is the most recent version of a large epidemiological study funded by the Bill and Melinda Gates Foundation and coordinated by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. In the...

2014-04-11 12:57:21

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV). As part of a compassionate use program, 104 post-liver transplant patients with recurring HCV who had exhausted all treatment options and had poor clinical prognoses, received sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) included at the physicians’ discretion for...


Latest Hepatitis Reference Libraries

Hepatitis B
2013-02-25 09:11:23

Image Caption: This electron micrograph reveals the presence of hepatitis-B virus HBV "Dane particles", or virions. Credit: CDC/Wikipedia Hepatitis B: What Is It? Hepatitis simply means a swelling or inflammation of the liver. The type hepatitis that a person contracts (there are 5 common forms) affects their long-term prognosis. The most common and most severe of these different types of liver infection is Hepatitis B, which is caused by the hepatitis B virus (HBV). It is typically...

69_3e2a06a821d939ffdc2eab851bee21e9
2011-01-24 12:50:52

Hepatitis A, caused by hepatitis A virus, is an acute infectious disease of the liver that is transmitted person to person by ingestion of contaminated food or water or through direct contact with an infectious person. Millions of people are believed to become infected with HAV every year. The incubation period is two to six weeks and on average is 28 days. In less developed countries the HAV is usually contracted in early childhood. Clean water helps to decrease contraction of HAV. In 90%...

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

45_36624a455e3cd9a4152b7670308f0ffa
2011-01-20 19:14:56

Hepatitis B virus, HBV, is a part of the Hepadnaviridae family of viruses. HBV can lead to cirrhosis and hepatocellular carcinoma and has been linked to pancreatic cancer. It is classified as a species of the Orthohepadnavirus. Similar viruses have been found worldwide in great apes and monkeys. There a few different genotypes and they all differ by at least 8% of the sequence and have distinct geographical distributions and this has been associated with anthropological history. Type A is...

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (5 articles) »